RxSight Inc

For the period ended Jun 30, 2024. Filed Aug 5, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 5, 2024

RXST$4.90+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Equity

CONDENSED CONSOLIDATED STATEMENTS OFSTOCKHOLDERS’ EQUITY

(In thousands, except number of shares)

Common stock · Additional paid-in · Accumulated other · Accumulated · Total stockholders'
Shares · Amount · capital · comprehensive loss · deficit · equity
Balance at December 31, 2023	36,139,513		$36		$754,971	$(5)		$(594,640)		$160,362
Shares issued for the exercise of stock options and vesting of restricted stock units	1,061,336		1		10,152	—		—		10,153
Shares redeemed for employee tax withholdings	(39,096)		—		(2,134)	—		—		(2,134)
Stock-based compensation expense	—		—		4,696	—		—		4,696
Unrealized loss on short-term investments and cash equivalents, net of tax	—		—		—	(45)		—		(45)
Foreign currency translation adjustment	—		—		—	(3)		—		(3)
Net loss	—		—		—	—		(9,100)		(9,100)
Balance at March 31, 2024	37,161,753		$37		$767,685	$(53)		$(603,740)		$163,929
Shares issued for the exercise of stock options and vesting of restricted stock units	363,105		1		3,102	—		—		3,103
Stock-based compensation expense		—		6,105			—		6,105
Shares issued for the employee stock purchase plan	38,905		—		737	—		—		737
Issuance of common stock for public offering, net of underwriting discounts, commissions and offering costs	2,053,571		2		107,475	—		—		107,477
Unrealized loss on short-term investments and cash equivalents, net of tax	—		—		—	(64)		—		(64)
Foreign currency translation adjustment	—		—		—	(1)		—		(1)
Net loss	—		—		—	—		(6,079)		(6,079)
Balance at June 30, 2024	39,617,334		$40		$885,104	$(118)		$(609,819)		$275,207

See accompanying notes to unaudited condensed consolidated financial statements

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except number of shares)

Common stock · Additional paid-in · Accumulated other · Accumulated · Total stockholders'
	Shares	Amount	capital	comprehensive loss	deficit	equity
Balance at December 31, 2022	28,268,389	$28	$636,001	$(95)	$(546,032)	$89,902
Shares issued for the exercise of stock options and vesting of restricted stock units	243,598	—	761	—	—	761
Shares redeemed for employee tax withholdings	(24,631)	—	(337)	—	—	(337)
Stock-based compensation expense	—	—	3,295	—	—	3,295
Issuance of common stock for public offering, net of underwriting discounts, commissions and offering costs	4,600,000	5	53,595	—	—	53,600
Issuance of common stock for at-the-market offerings, net of issuance costs	879,341	1	10,913	—	—	10,914
Unrealized gain on short-term investments and cash equivalents, net of tax	—	—	—	84	—	84
Foreign currency translation adjustment	—	—	—	2	—	2
Net loss	—	—	—	—	(13,212)	(13,212)
Balance at March 31, 2023	33,966,697	$34	$704,228	$(9)	$(559,244)	$145,009
Shares issued for the exercise of stock options and vesting of restricted stock units	316,092	—	2,599	—	—	2,599
Stock-based compensation expense	—	—	3,955	—	—	3,955
Shares issued for the employee stock purchase plan	50,504	—	536	—	—	536
Issuance of common stock for at-the-market offerings, net of issuance costs	834,748	1	18,956	—	—	18,957
Unrealized loss on short-term investments and cash equivalents, net of tax	—	—	—	(65)	—	(65)
Foreign currency translation adjustment	—	—	—	1	—	1
Net loss	—	—	—	—	(13,804)	(13,804)
Balance at June 30, 2023	35,168,041	$35	$730,274	$(73)	$(573,048)	$157,188

See accompanying notes to unaudited condensed consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.